Jamie Kang

[Cancer Letters] The authors synthesize the evolving biomarker landscape across genetic, immune, proteomic, and digital/imaging biomarkers. They highlight subtype-specific differences in mucosal, acral, and uveal melanoma, where biomarker patterns and therapeutic responses diverge markedly from those of cutaneous disease.

[Galderma] Galderma announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.

[Journal of Nanobiotechnology] Scientists demonstrated that plant-derived exosome-like nanoparticles represent a novel and effective nanotherapeutic strategy for lymphedema by orchestrating metabolic reprogramming and inhibiting fibrosis.

[Journal of Translational Medicine] Investigators identified a Piezo1/Yes-associated protein 1 (YAP1)/glutaminase 1 (GLS1) axis linking mechanical stress to metabolic reprogramming and fibroblast activation in bladder outlet obstruction, which may serve as a therapeutic target to prevent fibrosis and preserve bladder function.

[American Journal of Respiratory Cell and Molecular Biology] Researchers showed that fibroblast growth factor 2 stimulated proliferation and expression of various fibrotic markers in human pulmonary fibroblasts from healthy donors and idiopathic pulmonary fibrosis patients.

[Scientific Reports] Researchers investigated cell adhesion molecule 1 (CADM1) function in connective tissue mast cells (CTMCs) using a monoclonal antibody against the extracellular domain of CADM1, termed 3E1.